+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats



Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats



Archives of Pharmacal Research 32(1): 133-138



This study was to investigate the effect of kaempferol on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats. The oral (6 mg/kg) or intravenous (2 mg/kg) etoposide was administered to rats alone or 30 min after the oral kaempferol (1, 4, or 12 mg/kg) administration. Compared to the oral control group, the presence of kaempferol significantly (4 mg/kg, P < 0.05; 12 mg/kg, P < 0.01) increased the area under the plasma concentrationtime curve (AUC) and the peak concentration (C(max)) of the oral etoposide. Kaempferol decreased significantly (4 or 12 mg/kg, P < 0.05) the total body clearance (CL/F) of oral etoposide, while there was no significant change in the terminal halflife (t(1/2)), the elimination rate constant (K(el)) and the time to reach the peak concentration (T(max)) of etoposide in the presense of kaempferol. Consequently, the absolute bioavailability (AB%) of oral etoposide with kaempferol was significantly higher (4 mg/kg, P < 0.05; 12 mg/kg, P < 0.01) than those from the control group. Compared to the intravenous control group, the presence of kaempferol enhanced the AUC of intravenously administered etoposide, however, only presence of 12 mg/kg of kaempferol significant (P < 0.05) increased AUC of etoposide. The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol. The dosage regimen of etoposide should be taken into consideration for potential drug interaction when combined with kaempferol or dietary supplements containing kaempferol in patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 052982352

Download citation: RISBibTeXText

PMID: 19183886

DOI: 10.1007/s12272-009-1127-z


Related references

Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Research 29(4): 1411-1415, 2009

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Journal of Clinical Oncology 14(7): 2020-2030, 1996

Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide. Anti-Cancer Drugs 5(5): 602-603, 1994

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. Journal of Clinical Oncology 13(11): 2835-2841, 1995

Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer ChemoTherapy and Pharmacology 36(4): 352-355, 1995

Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. Archives of Medical Research 30(3): 212-215, 1999

Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. European Journal of Drug Metabolism and Pharmacokinetics 33(3): 159-164, 2008

Preformulation study of etoposide identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharmaceutical Research (New York) 6(53): 408-412, 1989

Simultaneous determination of etoposide and a piperine analogue by UPLC-qTOF-MS evidence that PA-1 enhances the oral bioavailability of etoposide in mice. Journal Of Chromatography, B8: 9 10, 823-830, 2010

Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 878(9-10): 823-830, 2010

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. British Journal of Cancer 86(1): 12-13, 7 January, 2002

Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Seminars in Oncology 23(6 Suppl 13): 23-29, 1996

Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous etoposide. American Journal of Clinical Oncology 23(1): 65-67, 2000

Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Annals of Oncology 5(1): 90-92, 1994

Relationships between hematological toxicity and total and free etoposide plasmatic levels with daily oral etoposide administration. Bulletin du Cancer 82(8): 660-664, 1995